Newron Pharmaceuticals

Newron Pharmaceuticals SpA: Expanding Global and U.S. Investor & Partner Visibility

The Change They Wanted:

  • Newron is a Swiss-traded biopharmaceutical company focused on therapies for patients with diseases of the CNS.
  • New breakthrough data presented supporting that evenamide for schizophrenia impacts long-term brain plasticity changes in its extended therapeutic actions.
  • Build global visibility and, expand understanding with, sell-side analysts, potential partners/licensees, investors and investment banking community.

 

 

What We Did:

  • Execute a globally viewed scientific and investor-oriented R&D Day to increase investor and partner visibility.
  • Develop a US-centric marketing strategy for the event, including message and presentation development, event and location branding and broadcast.
  • Audience acquisition through extensive media relations, press release distribution, focused email campaigns and personal investor and partner outreach.

The Change We Delivered:

  • Secured the participation of the world’s leading experts in neurobiology, psychiatry and schizophrenia as speakers.
  • Live video of three leading schizophrenia KOL experts, elevating Newron’s presence and market shaping
  • 35 in-person attendees, including representatives from 5 investment banks and 9 sell-side analysts.
  • More than 200 live webcast participants from 7 countries worldwide.
  • Global webcast of event listened to for more than 700 total hours in more than 400 live and on-demand sessions

  • All Case Studies